A Novo Nordisk production facility in Denmark where semaglutide, the active ingredient in its weight loss and type 2 diabetes ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Around 2.3 million Medicare patients used Novo drugs made with semaglutide - which includes ... Shares in Novo Nordisk were already down before the publication of the list due to new obesity ...